Aprea Therapeutics (APRE) to Release Earnings on Wednesday

Aprea Therapeutics (NASDAQ:APRE) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Aprea Therapeutics to post earnings of ($0.22) per share and revenue of $0.0030 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:00 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. The firm had revenue of $0.00 million during the quarter. On average, analysts expect Aprea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Up 0.3%

Shares of APRE opened at $0.84 on Wednesday. The stock has a market cap of $10.44 million, a P/E ratio of -0.43 and a beta of 1.48. The business’s 50 day moving average price is $0.82 and its 200-day moving average price is $0.95. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.22.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

APRE has been the subject of several analyst reports. Wedbush restated an “outperform” rating and set a $7.00 price target on shares of Aprea Therapeutics in a report on Tuesday, March 31st. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright decreased their target price on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a report on Tuesday, March 31st. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.10.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.